HOOKIPA Pharma Inc. (HOOK)
Stock Price:
$10.30 USD
-0.41 (-3.83%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
264.14M |
| Revenue (ttm) |
13.40M |
| Net Income (ttm) |
-44.63M |
| Shares Out |
21.83M |
| EPS (ttm) |
-1.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$10.30 |
| Previous Close |
$10.71 |
| Change ($) |
-0.41 |
| Change (%) |
-3.83% |
| Day's Open |
10.53 |
| Day's Range |
9.92 - 10.92 |
| Day's Volume |
93,921 |
| 52-Week Range |
5.80 - 14.37 |
More Stats
| Market Cap |
264.14M |
| Enterprise Value |
169.87M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
21.83M |
| Float |
9.58M |
| EPS (basic) |
-1.78 |
| EPS (diluted) |
-1.86 |
| FCF / Share |
-1.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
753,078 |
| Short Ratio |
8.25 |
| Short % of Float |
4.91% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.71 |
| PB Ratio |
2.56 |
| Revenue |
13.40M |
| Operating Income |
-52.89M |
| Net Income |
-44.63M |
| Free Cash Flow |
-38.60M |
| Net Cash |
94.27M |
| Net Cash / Share |
3.68 |
| Gross Margin |
-256.44% |
| Operating Margin |
-394.61% |
| Profit Margin |
-333.00% |
| FCF Margin |
-288.00% |
| ROA |
-27.78% |
| ROE |
-49.33% |
| ROIC |
-166.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.00*
(84.47% upside)
Low
15.0
Current: 10.30
High
24.0
Target: 19.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 11.94 | 7.63 | - |
| Revenue Growth | 56.53% | - | - |
| Gross Profit | 11.94 | 7.63 | - |
| Operating Income | -51.09 | -21.18 | -14.16 |
| Net Income | -43.04 | -16.24 | -12.72 |
| Shares Outstanding | 17.86 | 0.91 | 0.91 |
| Earnings Per Share | -2.41 | -17.76 | -13.95 |
| Operating Cash Flow | -41.73 | -15.00 | -11.91 |
| Capital Expenditures | -2.00 | -2.15 | -1.30 |
| Free Cash Flow | -43.73 | -17.15 | -13.21 |
| Cash & Equivalents | 113 | 48.58 | 61.36 |
| Total Debt | 10.60 | 4.39 | 3.74 |
| Net Cash / Debt | 103 | 44.19 | 57.62 |
| Assets | 144 | 68.25 | 73.73 |
| Liabilities | 25.85 | 23.85 | 11.61 |
| Book Value | 118 | -60.38 | -42.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
HOOKIPA Pharma Inc. |
| Country |
United States |
| Employees |
85 |
| CEO |
Jörn Aldag |
Stock Information
| Ticker Symbol |
HOOK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HOOK |
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.